"Teladoc has been a good idea that I think we can come back to lower," Hedgeye CEO Keith McCullough writes. "This is mainly a market call in addition to TDOC signaling immediate-term #overbought."
***No change to Healthcare analyst Tom Tobin's fundamental long thesis on Teladoc. Click here to read our analyst's original report.
